# SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

> **NCT06288893** · PHASE2 · UNKNOWN · sponsor: **JKT Biopharma Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** SHEN211 Tablets
- **PROCEDURE:** Placebo for SHEN211 Tablets

## Key facts

- **NCT ID:** NCT06288893
- **Lead sponsor:** JKT Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-04-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06288893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06288893, "SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06288893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*